{
  "$schema": "folio-library-document/v1",
  "id": "10665-329296",
  "title": "Le diagnostic du VIH et l’utilisation des ARV chez le nourrisson exposé au virus : mise à jour programmatique",
  "variant": "pdf",
  "pages": 24,
  "tocSource": "inferred",
  "tocMethod": "font",
  "toc": [
    {
      "level": 1,
      "title": "WHO/CDS/HIV/18.17",
      "number": null,
      "page": 2,
      "pageLabel": "2",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-whocdshiv1817"
    },
    {
      "level": 1,
      "title": "© Organisation mondiale de la Santé 2018",
      "number": null,
      "page": 2,
      "pageLabel": "2",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-organisation-mondiale-de-la-santé-2018"
    },
    {
      "level": 1,
      "title": "RÉSUMÉ EXECUTIF",
      "number": "1.1",
      "page": 3,
      "pageLabel": "3",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-002-11-résumé-executif"
    },
    {
      "level": 1,
      "title": "ABRÉVIATIONS",
      "number": null,
      "page": 3,
      "pageLabel": "3",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-003-abréviations"
    },
    {
      "level": 1,
      "title": "CONTEXTE",
      "number": "2.1",
      "page": 4,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-004-21-contexte"
    },
    {
      "level": 2,
      "title": "Le Statu quo concernant l’infection à VIH chez le nourrisson et l’enfant",
      "number": "2.1.1",
      "page": 4,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-005-211-le-statu-quo-concernant-linfection-à-vih-che"
    },
    {
      "level": 2,
      "title": "Justification de cette mise à jour technique",
      "number": "2.1.2",
      "page": 5,
      "pageLabel": "5",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-006-212-justification-de-cette-mise-à-jour-technique"
    },
    {
      "level": 1,
      "title": "PRINCIPALES CONSIDÉRATIONS",
      "number": "3.0",
      "page": 5,
      "pageLabel": "5",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-007-30-principales-considérations"
    },
    {
      "level": 1,
      "title": "Diagnostic chez le nourrisson",
      "number": "3.1",
      "page": 5,
      "pageLabel": "5",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-008-31-diagnostic-chez-le-nourrisson"
    },
    {
      "level": 2,
      "title": "Réduire le nombre de résultats faux positifs en introduisant une fourchette indéterminée pour le DPN",
      "number": "3.1.1",
      "page": 5,
      "pageLabel": "5",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-009-311-réduire-le-nombre-de-résultats-faux-positifs"
    },
    {
      "level": 2,
      "title": "Tests de confirmation de résultats positifs",
      "number": "3.1.2",
      "page": 6,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-010-312-tests-de-confirmation-de-résultats-positifs"
    },
    {
      "level": 2,
      "title": "Gérer les résultats discordants et les interruptions de traitement",
      "number": "3.1.2",
      "page": 7,
      "pageLabel": "7",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-011-312-gérer-les-résultats-discordants-et-les-inter"
    },
    {
      "level": 2,
      "title": "Mise en œuvre du DPN sur le lieu des soins",
      "number": "3.1.3",
      "page": 8,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-012-313-mise-en-œuvre-du-dpn-sur-le-lieu-des-soins"
    },
    {
      "level": 2,
      "title": "Introduction du TAAN à la naissance pour faciliter une mise sous traitement plus rapide",
      "number": "3.1.4",
      "page": 8,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-013-314-introduction-du-taan-à-la-naissance-pour-fac"
    },
    {
      "level": 2,
      "title": "Kenya",
      "number": null,
      "page": 9,
      "pageLabel": "9",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-014-kenya"
    },
    {
      "level": 2,
      "title": "Zimbabwe",
      "number": null,
      "page": 9,
      "pageLabel": "9",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-015-zimbabwe"
    },
    {
      "level": 2,
      "title": "République démocratique du Congo",
      "number": null,
      "page": 9,
      "pageLabel": "9",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-016-république-démocratique-du-congo"
    },
    {
      "level": 2,
      "title": "Eswatini",
      "number": null,
      "page": 9,
      "pageLabel": "9",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-017-eswatini"
    },
    {
      "level": 2,
      "title": "Assurer une interprétation correcte du test à 9 mois et simplifier l’algorithme de dépistage",
      "number": "3.1.5",
      "page": 11,
      "pageLabel": "11",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-018-315-assurer-une-interprétation-correcte-du-test"
    },
    {
      "level": 1,
      "title": "Utilisation des ARV pour la prévention et le traitement de l’infection à VIH chez le nourrisson",
      "number": "3.2",
      "page": 12,
      "pageLabel": "12",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-019-32-utilisation-des-arv-pour-la-prévention-et-le"
    },
    {
      "level": 2,
      "title": "Defis de mise en œuvre d’une PPNa chez le nourrisson à haut risque",
      "number": "3.2.1",
      "page": 12,
      "pageLabel": "12",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-020-321-defis-de-mise-en-œuvre-dune-ppna-chez-le-nou"
    },
    {
      "level": 2,
      "title": "Traitement précoce du nourrisson: options limitées et complexité de l’administration",
      "number": "3.2.2",
      "page": 13,
      "pageLabel": "13",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-021-322-traitement-précoce-du-nourrisson-options-lim"
    },
    {
      "level": 1,
      "title": "Améliorer la prestation des services et mettre en place un module de soins postnatals",
      "number": "3.3",
      "page": 14,
      "pageLabel": "14",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-022-33-améliorer-la-prestation-des-services-et-mettr"
    },
    {
      "level": 2,
      "title": "Diagnostic chez le nourrisson",
      "number": null,
      "page": 15,
      "pageLabel": "15",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-023-diagnostic-chez-le-nourrisson"
    },
    {
      "level": 2,
      "title": "Prophylaxie et traitement du nourrisson",
      "number": null,
      "page": 15,
      "pageLabel": "15",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-024-prophylaxie-et-traitement-du-nourrisson"
    },
    {
      "level": 2,
      "title": "Prestation de services et module de soins postnatals",
      "number": null,
      "page": 15,
      "pageLabel": "15",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-025-prestation-de-services-et-module-de-soins-postna"
    },
    {
      "level": 1,
      "title": "RÉCAPITULATIF ET MESURES À PRENDRE",
      "number": "4",
      "page": 15,
      "pageLabel": "15",
      "confidence": 0.9,
      "evidence": [
        "style",
        "number",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-026-4-récapitulatif-et-mesures-à-prendre"
    },
    {
      "level": 2,
      "title": "REMERCIEMENTS",
      "number": null,
      "page": 16,
      "pageLabel": "16",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-027-remerciements"
    },
    {
      "level": 3,
      "title": "Participants à la réunion",
      "number": null,
      "page": 16,
      "pageLabel": "16",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-028-participants-à-la-réunion"
    },
    {
      "level": 3,
      "title": "Membres du personnel de l’OMS",
      "number": null,
      "page": 16,
      "pageLabel": "16",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-029-membres-du-personnel-de-loms"
    },
    {
      "level": 2,
      "title": "RÉFÉRENCES BIBLIOGRAPHIQUES",
      "number": null,
      "page": 17,
      "pageLabel": "17",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-030-références-bibliographiques"
    },
    {
      "level": 2,
      "title": "ANNEXES",
      "number": null,
      "page": 18,
      "pageLabel": "18",
      "confidence": 0.8,
      "evidence": [
        "style",
        "numbered-style",
        "stock-name"
      ],
      "source": "inferred",
      "section": "sec-031-annexes"
    },
    {
      "level": 2,
      "title": "Annexe 1: Mode opératoire normalisé à suivre pour les résultats indéterminés",
      "number": null,
      "page": 18,
      "pageLabel": "18",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-032-annexe-1-mode-opératoire-normalisé-à-suivre-pour"
    },
    {
      "level": 2,
      "title": "Annexe 2: Procédure à suivre en cas de résultats discordants et d’interruption d’un traitement",
      "number": null,
      "page": 19,
      "pageLabel": "19",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-033-annexe-2-procédure-à-suivre-en-cas-de-résultats"
    },
    {
      "level": 3,
      "title": "DPN et charge virale 4 semaines, 4 mois et 8 mois après l’interruption",
      "number": null,
      "page": 19,
      "pageLabel": "19",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-034-dpn-et-charge-virale-4-semaines-4-mois-et-8-mois"
    },
    {
      "level": 4,
      "title": "TAAN 1: +",
      "number": null,
      "page": 19,
      "pageLabel": "19",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-035-taan-1"
    },
    {
      "level": 4,
      "title": "TAAN 2: -",
      "number": null,
      "page": 19,
      "pageLabel": "19",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-036-taan-2"
    },
    {
      "level": 4,
      "title": "TAAN 3: -",
      "number": null,
      "page": 19,
      "pageLabel": "19",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-037-taan-3"
    },
    {
      "level": 2,
      "title": "Annexe 3: Algorithme simplifié pour le DPN",
      "number": null,
      "page": 20,
      "pageLabel": "20",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-038-annexe-3-algorithme-simplifié-pour-le-dpn"
    },
    {
      "level": 2,
      "title": "Annexe 4: Algorithme pour l’évaluation du risque d’infection",
      "number": null,
      "page": 21,
      "pageLabel": "21",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-039-annexe-4-algorithme-pour-lévaluation-du-risque-d"
    },
    {
      "level": 3,
      "title": "La mère a-t-elle été sous TAR pendant >4 semaines avant l’accouchement",
      "number": null,
      "page": 21,
      "pageLabel": "21",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-040-la-mère-a-t-elle-été-sous-tar-pendant-4-semaines"
    },
    {
      "level": 3,
      "title": "Connaît-on la charge virale moins de",
      "number": null,
      "page": 21,
      "pageLabel": "21",
      "confidence": 0.6,
      "evidence": [
        "style"
      ],
      "source": "inferred",
      "section": "sec-041-connaît-on-la-charge-virale-moins-de"
    },
    {
      "level": 2,
      "title": "Annexe 5: Posologie et formes galéniques pour la prophylaxie chez le nourrisson",
      "number": null,
      "page": 22,
      "pageLabel": "22",
      "confidence": 0.7,
      "evidence": [
        "style",
        "numbered-style"
      ],
      "source": "inferred",
      "section": "sec-042-annexe-5-posologie-et-formes-galéniques-pour-la"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 2,
      "labelStart": null,
      "labelEnd": "2",
      "words": 22,
      "summary": {
        "text": "The French-language cover of the July 2018 WHO technical report giving a programmatic update on HIV diagnosis and antiretroviral use in HIV-exposed infants.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "LE DIAGNOSTIC DU VIH ET L’UTILISATION DES ARV CHEZ LE NOURRISSON EXPOSÉ AU VIRUS: MISE A JOUR PROGRAMMATIQUE JUILLET 2018 RAPPORT TECHNIQUE",
      "extractCut": false,
      "blocks": [
        "library/10665-329296/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-whocdshiv1817",
      "number": null,
      "title": "WHO/CDS/HIV/18.17",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 2,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-001-organisation-mondiale-de-la-santé-2018",
      "number": null,
      "title": "© Organisation mondiale de la Santé 2018",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 3,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 577,
      "summary": {
        "text": "The French-language copyright and licence page of the 2018 WHO report on infant HIV diagnosis and ARV use, with Creative Commons terms, citation details and disclaimers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "organisation mondiale",
          "heading": true
        },
        {
          "term": "présente œuvre",
          "heading": false
        },
        {
          "term": "présente traduction",
          "heading": false
        },
        {
          "term": "présente publication",
          "heading": false
        },
        {
          "term": "cette œuvre",
          "heading": false
        },
        {
          "term": "licence creative",
          "heading": false
        },
        {
          "term": "droit auteur",
          "heading": false
        },
        {
          "term": "produits commerciaux",
          "heading": false
        }
      ],
      "extract": "Certains droits réservés. La présente publication est disponible sous la licence Creative Commons Attribution - Pas d’utilisation commerciale - Partage dans les mêmes conditions 3.0 IGO (CC BY-NC-SA 3.0 IGO ; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Aux termes de cette licence, vous pouvez copier, distribuer et adapter l’œuvre à des fins non commerciales, pour autant que l’œuvre soit citée de manière",
      "extractCut": true
    },
    {
      "id": "sec-002-11-résumé-executif",
      "number": "1.1",
      "title": "RÉSUMÉ EXECUTIF",
      "level": 1,
      "pageStart": 3,
      "pageEnd": 3,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 272,
      "summary": {
        "text": "A French-language executive summary noting that children are still being infected with HIV and that the 2016 WHO consolidated ARV guidelines introduced approaches such as nucleic acid testing at birth. It explains that this update, following a 2018 Geneva meeting, describes changes in infant testing, prevention and treatment and emphasises a postnatal care package for exposed infants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vih chez",
          "heading": false
        },
        {
          "term": "sur les",
          "heading": false
        },
        {
          "term": "directrices unifiées",
          "heading": false
        },
        {
          "term": "des enfants",
          "heading": false
        },
        {
          "term": "dans les",
          "heading": false
        },
        {
          "term": "lignes directrices",
          "heading": false
        },
        {
          "term": "nourrisson",
          "heading": false
        },
        {
          "term": "traitement",
          "heading": false
        }
      ],
      "extract": "Partout dans le monde, des enfants continuent d’être infectés par le VIH et le diagnostic et le traitement des nourrissons et des enfants vivant avec le virus dans les meilleurs délais reste toujours d’une importance critique. La version 2016 des Lignes directrices unifiées de l’OMS sur l’utilisation des antirétroviraux pour le traitement et la prévention de l’infection à VIH contenues dans le document 2016 WHO ARV",
      "extractCut": true
    },
    {
      "id": "sec-003-abréviations",
      "number": null,
      "title": "ABRÉVIATIONS",
      "level": 1,
      "pageStart": 3,
      "pageEnd": 4,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 65,
      "summary": {
        "text": "A French-language list of abbreviations used in the report, such as those for antiretroviral drugs, early infant diagnosis and mother-to-child transmission.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "transmission mère-enfant",
          "heading": false
        },
        {
          "term": "normalisé",
          "heading": false
        },
        {
          "term": "azidothymidine",
          "heading": false
        }
      ],
      "extract": "3TC lamivudine ADF association à dose fixe ARV antirétroviraux AZT azidothymidine (zidovudine) CTX cotrimoxazole DPN diagnostic précoce chez le nourrisson LPV/r lopinavir/ritonavir MON mode opératoire normalisé NVP névirapine PCR amplification génique PPNa prophylaxie postnatale améliorée PTME prévention de la transmission mère-enfant RAL raltégravir TAAN test d’amplification des acides nucléiques TAR traitement",
      "extractCut": true
    },
    {
      "id": "sec-004-21-contexte",
      "number": "2.1",
      "title": "CONTEXTE",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-005-211-le-statu-quo-concernant-linfection-à-vih-che",
      "number": "2.1.1",
      "title": "Le Statu quo concernant l’infection à VIH chez le nourrisson et l’enfant",
      "level": 2,
      "pageStart": 4,
      "pageEnd": 5,
      "labelStart": "4",
      "labelEnd": "5",
      "words": 637,
      "summary": {
        "text": "Describes the current situation of HIV among infants and children: the Global Plan sharply reduced new paediatric infections in priority sub-Saharan African countries, yet about 180 000 new child infections were reported in 2017, and the Start Free, Stay Free, AIDS Free framework was launched to carry progress forward towards ending AIDS by 2030. Wider antiretroviral therapy for pregnant women under Option B+ has lowered vertical transmission, but about half of new child infections now happen during breastfeeding, retaining women in care remains a challenge, and early infant diagnosis coverage is low, with a figure showing transmission rates by priority country. Only about half of children living with HIV were on treatment at the end of 2017, untreated infected infants face very high mortality, and suitable antiretroviral formulations for newborns and young infants remain scarce.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vih chez",
          "heading": true
        },
        {
          "term": "chez enfant",
          "heading": true
        },
        {
          "term": "infection vih",
          "heading": true
        },
        {
          "term": "nourrisson",
          "heading": true
        },
        {
          "term": "chez les",
          "heading": false
        },
        {
          "term": "les femmes",
          "heading": false
        },
        {
          "term": "les nouvelles",
          "heading": false
        },
        {
          "term": "dans les",
          "heading": false
        }
      ],
      "extract": "nourrisson et l’enfant L’initiative du Plan mondial pour éliminer les nouvelles infections à VIH chez les enfants à l’horizon 2015 et maintenir leur mères en vie a eu un impact considérable, conduisant à une réduction de 60% des nouveaux cas pédiatriques dans 21 pays à forte charge d’infection à VIH en Afrique subsaharienne.1,2 Le nombre des nouvelles infections à VIH chez l’enfant reste pourtant élevé: en 2017, 180",
      "extractCut": true
    },
    {
      "id": "sec-006-212-justification-de-cette-mise-à-jour-technique",
      "number": "2.1.2",
      "title": "Justification de cette mise à jour technique",
      "level": 2,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 465,
      "summary": {
        "text": "Explains the reasons for this technical update: few countries have yet implemented the 2016 WHO consolidated antiretroviral guidelines, and early adopters have raised issues such as more false-positive nucleic acid test results as transmission falls, delayed antibody development that complicates rapid tests in infants, operational barriers to testing at birth, difficulties with enhanced postnatal prophylaxis for high-risk infants, and the need for stronger postnatal care packages for exposed infants and their mothers. It notes that, after a WHO regional workshop in Johannesburg in June 2017, an expert meeting was held in April 2018, and that the update highlights the main changes and implementation considerations arising from the 2016 guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "les nourrissons",
          "heading": false
        },
        {
          "term": "pour les",
          "heading": false
        },
        {
          "term": "des approches",
          "heading": false
        },
        {
          "term": "nourrissons haut",
          "heading": false
        },
        {
          "term": "sur les",
          "heading": false
        },
        {
          "term": "plusieurs pays",
          "heading": false
        },
        {
          "term": "pays ont",
          "heading": false
        },
        {
          "term": "directrices unifiées",
          "heading": false
        }
      ],
      "extract": "Les Lignes directrices unifiées 2016 de l’OMS (2016 WHO ARV Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing VIH Infection)10 ont présenté des approches innovantes pour le diagnostic et le traitement, Cependant, à ce jour seuls quelques pays ont commencé à les mettre en œuvre. En outre, les données issues des premiers pays qui les ont adopté soulèvent de nombreux problèmes qui",
      "extractCut": true
    },
    {
      "id": "sec-007-30-principales-considérations",
      "number": "3.0",
      "title": "PRINCIPALES CONSIDÉRATIONS",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-008-31-diagnostic-chez-le-nourrisson",
      "number": "3.1",
      "title": "Diagnostic chez le nourrisson",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 126,
      "summary": {
        "text": "Explains that early infant HIV diagnosis has grown more complex with treat-all policies, enhanced postnatal prophylaxis, lower transmission and the larger role of postnatal transmission, so testing must now continue throughout the exposure period without delaying treatment for infants found to be infected.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dpn",
          "heading": false
        },
        {
          "term": "des tests",
          "heading": false
        },
        {
          "term": "tout",
          "heading": false
        },
        {
          "term": "exposition",
          "heading": false
        },
        {
          "term": "chez",
          "heading": true
        }
      ],
      "extract": "La complexité du DPN augmente à la suite de l’extension marquée de l’application de la politique qui vise à traiter tout le monde (y compris les femmes enceintes et allaitantes), de la mise en œuvre de la PPNa, de la diminution des taux de TME et du rôle proportionnellement plus important que joue la transmission postnatale. Le DPN ne peut plus être considéré avant tout comme fondé sur un seul test: des tests",
      "extractCut": true
    },
    {
      "id": "sec-009-311-réduire-le-nombre-de-résultats-faux-positifs",
      "number": "3.1.1",
      "title": "Réduire le nombre de résultats faux positifs en introduisant une fourchette indéterminée pour le DPN",
      "level": 2,
      "pageStart": 5,
      "pageEnd": 6,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 605,
      "summary": {
        "text": "Discusses how falling transmission rates and low viral levels in infected infants have increased false-positive early infant diagnosis results, so some infants may be wrongly started on lifelong treatment, while no guidance yet exists on what level counts as truly positive or on using an indeterminate range. Drawing on a systematic review of 32 studies and a follow-up study, it estimates that about 12.5% of non-negative initial results may be false positives where no indeterminate range is applied, and explains the choice of a cycle threshold of about 33 on a Roche assay as the optimal indeterminate cut-off, balancing missed infections against unnecessary treatment. It points to South Africa's and a new WHO standard operating procedure for handling indeterminate results and recommends retesting the original sample, which resolves most cases, before recalling the infant for a new specimen.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "fourchette indéterminée",
          "heading": true
        },
        {
          "term": "indéterminée pour",
          "heading": true
        },
        {
          "term": "une fourchette",
          "heading": true
        },
        {
          "term": "faux positifs",
          "heading": true
        },
        {
          "term": "introduisant",
          "heading": true
        },
        {
          "term": "dans les",
          "heading": false
        },
        {
          "term": "des cas",
          "heading": false
        },
        {
          "term": "dpn",
          "heading": true
        }
      ],
      "extract": "introduisant une fourchette indéterminée pour le DPN Si le diagnostic chez le nourrisson est plus souvent pratiqué un peu partout grâce au meilleur accès au « traitement pour tout le monde », on assiste cependant à une augmentation du nombre de faux positifs signalés dans les programmes à la suite de la baisse des taux de TME12 et de la faible virémie observée chez les nourrissons dont l’infection à VIH est",
      "extractCut": true
    },
    {
      "id": "sec-010-312-tests-de-confirmation-de-résultats-positifs",
      "number": "3.1.2",
      "title": "Tests de confirmation de résultats positifs",
      "level": 2,
      "pageStart": 6,
      "pageEnd": 7,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 503,
      "summary": {
        "text": "Reports a cost-effectiveness analysis showing that without confirmatory testing more than 10% of infants started on treatment could be uninfected where transmission is similar to South Africa, stresses retaining and testing all HIV-exposed infants and confirming every positive result, and includes a box defining diagnostic terms such as indeterminate range, false positives, false negatives, non-negative and discordant results, and cycle threshold. It concludes that, given new performance evidence and WHO prequalification of two point-of-care technologies, point-of-care early infant diagnosis may be used to confirm positive results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "résultats positifs",
          "heading": true
        },
        {
          "term": "dpn sur",
          "heading": false
        },
        {
          "term": "non infectés",
          "heading": false
        },
        {
          "term": "infectés diagnostiqués",
          "heading": false
        },
        {
          "term": "lieu des",
          "heading": false
        },
        {
          "term": "des soins",
          "heading": false
        },
        {
          "term": "les nourrissons",
          "heading": false
        },
        {
          "term": "soins pour",
          "heading": false
        }
      ],
      "extract": "Une analyse du rapport coût-efficacité effectuée pour déterminer la valeur d’un test de confirmation dans différents scénarios s’est révélée utile.16 En l’absence de tests de confirmation, cette analyse a démontré que dans des situations où les taux de TME étaient semblables à ceux observés en Afrique du Sud, plus de 10% des nourrissons mis sous TAR pouvaient en réalité être non infectés. Les tests de confirmation",
      "extractCut": true
    },
    {
      "id": "sec-011-312-gérer-les-résultats-discordants-et-les-inter",
      "number": "3.1.2",
      "title": "Gérer les résultats discordants et les interruptions de traitement",
      "level": 2,
      "pageStart": 7,
      "pageEnd": 8,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 787,
      "summary": {
        "text": "Discusses how to handle discordant infant HIV test results and when antiretroviral therapy may be stopped, listing conditions for interruption and for follow-up of infants whose treatment is halted. Describes South Africa's intensive 18-month monitoring policy and proposes a simpler option of qualitative and viral load testing at 4 weeks, 4 months and 8 months after interruption, with a return to treatment if any later test is positive. A box stresses prompt retesting of indeterminate results and priority confirmatory testing of all positive results until a final diagnosis is reached.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "résultats discordants",
          "heading": true
        },
        {
          "term": "les résultats",
          "heading": true
        },
        {
          "term": "suivi intensif",
          "heading": false
        },
        {
          "term": "traitement",
          "heading": true
        },
        {
          "term": "les nourrissons",
          "heading": false
        },
        {
          "term": "des nourrissons",
          "heading": false
        },
        {
          "term": "les mois",
          "heading": false
        },
        {
          "term": "mois après",
          "heading": false
        }
      ],
      "extract": "de traitement Depuis 2010, l’OMS recommande la mise sous TAR du nourrisson après un TAAN initial positif, et le prélèvement simultané d’un échantillon de confirmation. Les Lignes directrices unifiées 2016 de l’OMS10 indiquent que si le deuxième TAAN (de confirmation) se révèle négatif, il y a lieu de procéder à un troisième TAAN, DPN (qualitatif) ou test de la charge virale, avant d’envisager l’arrêt du TAR.",
      "extractCut": true
    },
    {
      "id": "sec-012-313-mise-en-œuvre-du-dpn-sur-le-lieu-des-soins",
      "number": "3.1.3",
      "title": "Mise en œuvre du DPN sur le lieu des soins",
      "level": 2,
      "pageStart": 8,
      "pageEnd": 8,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 368,
      "summary": {
        "text": "Explains that WHO's 2016 consolidated guidelines endorse nucleic acid tests validated for use at or near the point of care for early infant HIV diagnosis, citing studies in Malawi and Mozambique that showed faster results and quicker treatment start. Lists lessons from pilot projects, including site and product selection, maintenance arrangements, staff training, service linkages and the availability of paediatric antiretroviral formulations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lieu des",
          "heading": true
        },
        {
          "term": "des soins",
          "heading": true
        },
        {
          "term": "dpn sur",
          "heading": true
        },
        {
          "term": "utilisation des",
          "heading": false
        },
        {
          "term": "les délais",
          "heading": false
        },
        {
          "term": "pour les",
          "heading": false
        },
        {
          "term": "mise",
          "heading": true
        },
        {
          "term": "des services",
          "heading": false
        }
      ],
      "extract": "Les Lignes directrices unifiées 2016 de l’OMS10 recommandent l’utilisation des technologies TAAN qui ont été élaborées et validées pour l’utilisation sur le lieu des soins ou à proximité pour le dépistage précoce du VIH chez le nourrisson. Le DPN sur le lieu des soins offre la possibilité de réduire les délais d’obtention des résultats, de diminuer la perte de patients le long de la chaîne de dépistage du VIH, de",
      "extractCut": true
    },
    {
      "id": "sec-013-314-introduction-du-taan-à-la-naissance-pour-fac",
      "number": "3.1.4",
      "title": "Introduction du TAAN à la naissance pour faciliter une mise sous traitement plus rapide",
      "level": 2,
      "pageStart": 8,
      "pageEnd": 9,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 812,
      "summary": {
        "text": "Examines adding nucleic acid testing at birth to national infant diagnosis programmes, noting that it can bring treatment forward by about two months but that survival gains vanish if too many infants testing negative at birth are lost to follow-up. Lists implementation considerations such as reviewing the existing 6-week programme, collecting data in pilots, targeting high-risk infants, actively tracing infants and returning results quickly. Boxes note that two point-of-care technologies are WHO-prequalified and describe South Africa's 2015 introduction of birth testing, which was well accepted but hampered by weak linkage to care and low return for later tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "naissance",
          "heading": true
        },
        {
          "term": "mise sous",
          "heading": true
        },
        {
          "term": "sous traitement",
          "heading": true
        },
        {
          "term": "taan",
          "heading": true
        },
        {
          "term": "naissance est",
          "heading": false
        },
        {
          "term": "des nourrissons",
          "heading": false
        },
        {
          "term": "les nourrissons",
          "heading": false
        },
        {
          "term": "des visites",
          "heading": false
        }
      ],
      "extract": "une mise sous traitement plus rapide L’adjonction du TAAN à la naissance dans le programme national de dépistage du nourrisson pourrait permettre de repérer plus rapidement les nouveau-nés infectés par le VIH et donc de les mettre plus vite sous traitement et de diminuer les taux de mortalité infantile. Les données semblent montrer que les nourrissons testés positifs à la naissance sont mis sous TAR environ 2 mois",
      "extractCut": true
    },
    {
      "id": "sec-014-kenya",
      "number": null,
      "title": "Kenya",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 181,
      "summary": {
        "text": "Describes Kenya's 2015 pilot of nucleic acid testing within 72 hours of birth, which informed a revised infant diagnosis algorithm in 2016 and a national scale-up plan due to begin in mid-2018. Preparations included a dedicated testing point, a new referral register, mentor mothers and a psychosocial support group, while problems involved referral, demand creation, result turnaround, uncollected results and a lack of newborn drug formulations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "les mères",
          "heading": false
        },
        {
          "term": "les résultats",
          "heading": false
        },
        {
          "term": "naissance",
          "heading": false
        },
        {
          "term": "pour",
          "heading": false
        },
        {
          "term": "été",
          "heading": false
        },
        {
          "term": "des",
          "heading": false
        },
        {
          "term": "dépistage",
          "heading": false
        }
      ],
      "extract": "Le Kenya a introduit un projet pilote pour le TAAN à la naissance en 2015 (défini comme un dépistage dans les 72 heures suivant la naissance) et les résultats de ce projet ont formé la base d’un algorithme révisé pour le DPN en 2016 et d’un plan national d’extension devant commencer au milieu de 2018. Avant la mise en œuvre, un point central a été désigné dans l’établissement de santé pour le dépistage à la",
      "extractCut": true
    },
    {
      "id": "sec-015-zimbabwe",
      "number": null,
      "title": "Zimbabwe",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 111,
      "summary": {
        "text": "Reports on Zimbabwe's April 2017 pilot of point-of-care testing at birth for high-risk HIV-exposed infants in 10 facilities, where 97% of results reached caregivers and all infected infants began treatment within 5 days.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "des nourrissons",
          "heading": false
        },
        {
          "term": "nourrissons haut",
          "heading": false
        },
        {
          "term": "les nourrissons",
          "heading": false
        },
        {
          "term": "haut risque",
          "heading": false
        },
        {
          "term": "ont été",
          "heading": false
        }
      ],
      "extract": "Le Zimbabwe a commencé son projet pilote de TAAN sur le lieu des soins pour des nourrissons à haut risque exposés au VIH (<48 heures après la naissance) en avril 2017 dans 10 établissements de santé; 97% des résultats ont été transmis au personnel soignant et tous les nourrissons infectés ont été mis sous TAR dans les 5 jours suivant le dépistage. Ce projet devrait fournir de précieuses données sur une approche",
      "extractCut": true
    },
    {
      "id": "sec-016-république-démocratique-du-congo",
      "number": null,
      "title": "République démocratique du Congo",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 155,
      "summary": {
        "text": "Describes the Democratic Republic of the Congo's birth-testing pilot started in December 2016, with samples sent to central laboratories whose staff were trained to prioritise them. Long turnaround times of 8–12 weeks, stock-outs, sample transport problems and the early discharge of mothers limited the pilot, which has ended while the country strengthens its 6-week infant testing programme.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "des échantillons",
          "heading": false
        },
        {
          "term": "les difficultés",
          "heading": false
        },
        {
          "term": "des résultats",
          "heading": false
        },
        {
          "term": "naissance",
          "heading": false
        },
        {
          "term": "concerné",
          "heading": false
        },
        {
          "term": "semaines",
          "heading": false
        }
      ],
      "extract": "Le TAAN à la naissance a été mis en œuvre pour la première fois en décembre 2016, avec des échantillons envoyés aux laboratoires centraux pour analyse. Le personnel de laboratoire a été formé pour donner la priorité aux échantillons prélevés à la naissance et pour veiller au retour rapide des résultats à l’établissement de santé concerné. Les difficultés rencontrées ont notamment concerné: les longs délais entre la",
      "extractCut": true
    },
    {
      "id": "sec-017-eswatini",
      "number": null,
      "title": "Eswatini",
      "level": 2,
      "pageStart": 9,
      "pageEnd": 11,
      "labelStart": "9",
      "labelEnd": "11",
      "words": 327,
      "summary": {
        "text": "Reports on Eswatini's two birth-testing pilots begun in August 2017 at five maternity sites, comparing point-of-care and conventional testing in terms of coverage, infections detected and treatment started. Both pilots showed added workload for nurses, missed tests as mothers left early or gave wrong contact details, and follow-up difficulties, and the block ends with further considerations on linking infants to treatment and on quality coordination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "des nouveau-nés",
          "heading": false
        },
        {
          "term": "révélés infectés",
          "heading": false
        },
        {
          "term": "projet pilote",
          "heading": false
        },
        {
          "term": "les nouveau-nés",
          "heading": false
        },
        {
          "term": "nouveau-nés exposés",
          "heading": false
        },
        {
          "term": "été testés",
          "heading": false
        },
        {
          "term": "lieu des",
          "heading": false
        },
        {
          "term": "des soins",
          "heading": false
        }
      ],
      "extract": "L’Eswatini a introduit deux projets pilotes de TAAN à la naissance sur 5 sites de maternité en août 2017, faisant appel aux technologies de DPN sur le lieu des soins dans trois sites (en partenariat avec EGPAF) et au dépistage conventionnel dans deux sites (en partenariat avec ICAP). Dans le projet pilote conventionnel, 93% des nouveau-nés exposés au VIH ont été testés avant de quitter la maternité et 6 sur les 1548",
      "extractCut": true
    },
    {
      "id": "sec-018-315-assurer-une-interprétation-correcte-du-test",
      "number": "3.1.5",
      "title": "Assurer une interprétation correcte du test à 9 mois et simplifier l’algorithme de dépistage",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 12,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 901,
      "summary": {
        "text": "Explains that changing transmission dynamics, greater antiretroviral exposure and late maternal infection make the rapid diagnostic test at 9 months increasingly unreliable for ruling out infant HIV infection, citing findings from Uganda and Kenya. Proposes replacing it with a nucleic acid test at 9 months for all HIV-exposed infants and summarises the principles of the simplified algorithm in Annex 3, including maternal testing to establish exposure, confirmatory testing and regular follow-up until final diagnosis. A box sets out implementation considerations for rapid tests, such as prioritising maternal testing and not treating a negative infant result after 4 months as final.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "simplifier algorithme",
          "heading": true
        },
        {
          "term": "tdr mois",
          "heading": false
        },
        {
          "term": "nourrisson exposé",
          "heading": false
        },
        {
          "term": "tdr chez",
          "heading": false
        },
        {
          "term": "taan positif",
          "heading": false
        },
        {
          "term": "les tdr",
          "heading": false
        },
        {
          "term": "vih chez",
          "heading": false
        },
        {
          "term": "tdr pour",
          "heading": false
        }
      ],
      "extract": "à 9 mois et simplifier l’algorithme de dépistage Les Lignes directrices unifiées 2016 de l’OMS recommandent de recourir au TDR pour évaluer l’exposition au VIH du nourrisson âgé de moins de 4 mois, alors que l’exposition entre 4 et 18 mois doit être vérifiée au moyen d’un dépistage chez la mère. Si celui-ci n’est pas possible, les lignes directrices actuelles soulignent qu’il est important de ne pas considérer un",
      "extractCut": true
    },
    {
      "id": "sec-019-32-utilisation-des-arv-pour-la-prévention-et-le",
      "number": "3.2",
      "title": "Utilisation des ARV pour la prévention et le traitement de l’infection à VIH chez le nourrisson",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 10,
      "summary": {
        "text": "A fragment of a section heading on the use of antiretrovirals to prevent and treat HIV infection in infants.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "et le traitement de l’infection à VIH chez le nourrisson",
      "extractCut": false
    },
    {
      "id": "sec-020-321-defis-de-mise-en-œuvre-dune-ppna-chez-le-nou",
      "number": "3.2.1",
      "title": "Defis de mise en œuvre d’une PPNa chez le nourrisson à haut risque",
      "level": 2,
      "pageStart": 12,
      "pageEnd": 13,
      "labelStart": "12",
      "labelEnd": "13",
      "words": 1231,
      "summary": {
        "text": "Sets out WHO's 2016 recommendation of AZT plus NVP prophylaxis for up to 12 weeks for breastfed infants at high risk of HIV transmission, defines high risk and describes how different countries have adopted enhanced postnatal prophylaxis. Notes that giving it to all exposed infants raises cost and toxicity and should only be a temporary measure, and discusses situations where maternal viral suppression cannot be assured and prophylaxis might be extended. Raises the option of presumptive triple-drug treatment for infants of mothers diagnosed late or newly infected, with attention to its effect on infant testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "haut risque",
          "heading": true
        },
        {
          "term": "nourrisson",
          "heading": true
        },
        {
          "term": "ppna",
          "heading": true
        },
        {
          "term": "prophylaxie chez",
          "heading": false
        },
        {
          "term": "une prophylaxie",
          "heading": false
        },
        {
          "term": "virale chez",
          "heading": false
        },
        {
          "term": "ppna est",
          "heading": false
        },
        {
          "term": "semaines chez",
          "heading": false
        }
      ],
      "extract": "nourrisson à haut risque Les Lignes directrices unifiées 2016 de l’OMS recommandent un traitement associant l’AZT et la NVP qui peut être prolongé jusqu’à 12 semaines chez le nourrisson allaité par la mère et fortement exposé au risque de TME. Est considéré comme sujet à haut risque, le nourrisson dont la mère a été identifiée VIH positive pour la première fois au moment de l’accouchement ou lors du postpartum, ou",
      "extractCut": true
    },
    {
      "id": "sec-021-322-traitement-précoce-du-nourrisson-options-lim",
      "number": "3.2.2",
      "title": "Traitement précoce du nourrisson: options limitées et complexité de l’administration",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 14,
      "labelStart": "13",
      "labelEnd": "14",
      "words": 659,
      "summary": {
        "text": "Discusses early antiretroviral treatment for infants diagnosed at birth, noting that it improves survival but early mortality stays high and treatment options at that age are limited, for example AZT/3TC/NVP until three months followed by an LPV/r-based regimen, and reports the recent US FDA approval of raltegravir granules for term newborns of normal weight. It advises countries planning birth testing to consider decentralizing newborn treatment by building health worker skills, securing supplies in peripheral facilities and extending referral links. A box on drug formulations for infant postnatal prophylaxis compares syrups, dispersible tablets and paediatric fixed-dose combinations, setting out the dosing problems and unwanted 3TC exposure of the AZT/3TC/NVP combination despite its wide availability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adf pédiatrique",
          "heading": false
        },
        {
          "term": "une adf",
          "heading": false
        },
        {
          "term": "nourrisson",
          "heading": true
        },
        {
          "term": "azt est",
          "heading": false
        },
        {
          "term": "formes galéniques",
          "heading": false
        },
        {
          "term": "les comprimés",
          "heading": false
        },
        {
          "term": "galéniques pour",
          "heading": false
        },
        {
          "term": "traitement",
          "heading": true
        }
      ],
      "extract": "et complexité de l’administration Un TAR précoce chez le nourrisson permet d’améliorer la survie et de réduire la morbidité à long terme, mais la mortalité reste forte au cours des premiers mois. L’introduction du TAAN à la naissance pourrait permettre de commencer le TAR avant l’âge de deux semaines. Or le seul traitement dont on dispose à cet âge contient depuis de nombreuses années l’association AZT/3TC/NVP. Ce",
      "extractCut": true
    },
    {
      "id": "sec-022-33-améliorer-la-prestation-des-services-et-mettr",
      "number": "3.3",
      "title": "Améliorer la prestation des services et mettre en place un module de soins postnatals",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 15,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 622,
      "summary": {
        "text": "Argues that effective HIV services for infants need a package combining several interventions rather than any single one, citing proven client-focused measures such as text-message reminders, financial incentives and involving male partners, and system-focused measures such as point-of-care testing, provider training and support, peer support and quality improvement. It stresses integrating HIV care into maternal, newborn and child health platforms and joint information systems so that mother–infant pairs stay in care until a final diagnosis, while noting the added workload for those services. It also highlights community engagement, including networks of women living with HIV, in reducing loss to follow-up, and ends with the heading of a box on key research priorities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "des soins",
          "heading": true
        },
        {
          "term": "des services",
          "heading": true
        },
        {
          "term": "couple mère-enfant",
          "heading": false
        },
        {
          "term": "soins aux",
          "heading": false
        },
        {
          "term": "vih pour",
          "heading": false
        },
        {
          "term": "les services",
          "heading": false
        },
        {
          "term": "utilisation des",
          "heading": false
        },
        {
          "term": "avec les",
          "heading": false
        }
      ],
      "extract": "et mettre en place un module de soins postnatals Pour mettre en place des services efficaces contre le VIH pour le nourrisson, différents obstacles doivent être surmontés et aucune intervention ne permet à elle seule de régler tous les problèmes auxquels la mère et le nourrisson se trouvent confrontés à différents moments et dans des situations diverses. Les facteurs socioéconomiques et traditionnels assurant le",
      "extractCut": true
    },
    {
      "id": "sec-023-diagnostic-chez-le-nourrisson",
      "number": null,
      "title": "Diagnostic chez le nourrisson",
      "level": 2,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 183,
      "summary": {
        "text": "Lists research priorities on infant HIV diagnosis, including the impact of an indeterminate range, the added value of birth testing and of limiting it to high-risk infants, and tracking tools such as barcodes. Further items cover combining birth testing with BCG vaccination, the timing of viral load testing in pregnant and breastfeeding women, the effect of maternal treatment and infant prophylaxis on diagnosis, and ways to retain infants until final diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nourrisson",
          "heading": true
        },
        {
          "term": "chez",
          "heading": true
        },
        {
          "term": "valeur ajoutée",
          "heading": false
        },
        {
          "term": "évaluer impact",
          "heading": false
        },
        {
          "term": "dépistage",
          "heading": false
        },
        {
          "term": "naissance",
          "heading": false
        },
        {
          "term": "dpn",
          "heading": false
        }
      ],
      "extract": "• Évaluer l’impact de la mise en œuvre d’une fourchette d’indétermination, surtout pour les tests effectués à différents moments et pour différents types d’échantillons et technologies. • Obtenir des données d’impact pour déterminer la valeur ajoutée du dépistage à la naissance dans le cadre du programme DPN. • Évaluer l’utilité d’un dépistage à la naissance limité aux seuls nourrissons à haut risque. • Mesurer",
      "extractCut": true
    },
    {
      "id": "sec-024-prophylaxie-et-traitement-du-nourrisson",
      "number": null,
      "title": "Prophylaxie et traitement du nourrisson",
      "level": 2,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 140,
      "summary": {
        "text": "Lists research priorities on infant prophylaxis and treatment, such as the dosing and safety of new antiretrovirals for newborns, better formulations, country experience of and adherence to enhanced prophylaxis, and the feasibility of triple-drug prophylaxis when the mother is diagnosed after delivery.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nourrisson",
          "heading": true
        },
        {
          "term": "ppna",
          "heading": false
        },
        {
          "term": "prophylaxie",
          "heading": true
        },
        {
          "term": "maternels",
          "heading": false
        },
        {
          "term": "des",
          "heading": false
        }
      ],
      "extract": "• Déterminer la posologie et l’innocuité des nouveaux ARV destinés à la prophylaxie ou au traitement du nouveau-né et du nourrisson. • Mettre au point des formes galéniques optimales et assurer l’introduction en temps opportun des ARV nouvellement recommandés pour le nouveau-né et le nourrisson. • Réunir des données sur les expériences des pays en matière de PPNa. • Comprendre la pertinence clinique des épisodes",
      "extractCut": true
    },
    {
      "id": "sec-025-prestation-de-services-et-module-de-soins-postna",
      "number": null,
      "title": "Prestation de services et module de soins postnatals",
      "level": 2,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 36,
      "summary": {
        "text": "Lists two action points for service delivery: combining interventions in a package and promoting integration so that infants stay in testing until final diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prestation",
          "heading": true
        },
        {
          "term": "module",
          "heading": true
        },
        {
          "term": "associer",
          "heading": false
        }
      ],
      "extract": "• Envisager d’associer plusieurs interventions dans le cadre d’un module visant à appuyer la prestation de services. • Promouvoir l’intégration pour faire en sorte que le nourrisson reste dans la chaîne de dépistage jusqu’au diagnostic final.",
      "extractCut": false
    },
    {
      "id": "sec-026-4-récapitulatif-et-mesures-à-prendre",
      "number": "4",
      "title": "RÉCAPITULATIF ET MESURES À PRENDRE",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 16,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 113,
      "summary": {
        "text": "Summarises that promising innovations should be scaled up while existing infant testing and early treatment systems remain the priority, with strategies adapted to changing contexts and more evidence built to guide national policy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "des",
          "heading": false
        },
        {
          "term": "traitement",
          "heading": false
        },
        {
          "term": "probantes",
          "heading": false
        },
        {
          "term": "interdépendance",
          "heading": false
        },
        {
          "term": "ajoute",
          "heading": false
        }
      ],
      "extract": "Plusieurs innovations inédites mises en œuvre par les pays et les partenaires ont montré des résultats prometteurs. Pendant que des interventions probantes sont reprises plus largement, il reste essentiel de privilégier le renforcement des systèmes existants qui appuient le dépistage du nourrisson et le traitement précoce. De plus, l’évolution de la dynamique des normes de transmission et de traitement ajoute à la",
      "extractCut": true
    },
    {
      "id": "sec-027-remerciements",
      "number": null,
      "title": "REMERCIEMENTS",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-028-participants-à-la-réunion",
      "number": null,
      "title": "Participants à la réunion",
      "level": 3,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 163,
      "summary": {
        "text": "Lists the meeting participants and their institutional affiliations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "chan school",
          "heading": false
        },
        {
          "term": "laura",
          "heading": false
        },
        {
          "term": "ministère",
          "heading": false
        },
        {
          "term": "university",
          "heading": false
        },
        {
          "term": "harvard",
          "heading": false
        },
        {
          "term": "stellenbosch",
          "heading": false
        },
        {
          "term": "chai",
          "heading": false
        },
        {
          "term": "université",
          "heading": false
        }
      ],
      "extract": "Adolfo Vubil (INS Mozambique), Ahmed Haeri Mazanderai (University of Pretoria), Andrea Ciaranello (Harvard Medical School), Angela Mushavi (Ministère de la santé, Zimbabwe), Anna Laura Ross (Unitaid), Archawin Rojanawiwat (Université Chulalongkorn), Arne Kroidl (Université de Munich), Charles Kiyaga (Ministère de la santé, Ouganda), David Sullivan (USAID), Debbie Boras (London School of Hygiene and Tropical",
      "extractCut": true
    },
    {
      "id": "sec-029-membres-du-personnel-de-loms",
      "number": null,
      "title": "Membres du personnel de l’OMS",
      "level": 3,
      "pageStart": 16,
      "pageEnd": 17,
      "labelStart": "16",
      "labelEnd": "17",
      "words": 16,
      "summary": {
        "text": "Lists the WHO staff members who contributed to the document.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Meg Doherty, Martina Penazzato, Lara Vojnov, Anisa Ghadrshenas, Serena Brusamento, Morkor Newman, Mercedes Perez, Fatim Jallow.",
      "extractCut": false
    },
    {
      "id": "sec-030-références-bibliographiques",
      "number": null,
      "title": "RÉFÉRENCES BIBLIOGRAPHIQUES",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 804,
      "summary": {
        "text": "The reference list of a WHO document on HIV diagnosis and care in infants, followed by stray fragments of a testing algorithm flowchart.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "directrices actuelles",
          "heading": false
        },
        {
          "term": "lignes directrices",
          "heading": false
        },
        {
          "term": "échantillon dpn",
          "heading": false
        },
        {
          "term": "suivre les",
          "heading": false
        },
        {
          "term": "infant diagnosis",
          "heading": false
        },
        {
          "term": "vih chez",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "infection vih",
          "heading": false
        }
      ],
      "extract": "BIBLIOGRAPHIQUES 1. UNAIDS. On the Fast-track to an AIDS-Free Generation. Geneva: UNAIDS; 2016. 2. ONUSIDA. Plan mondial pour éliminer les nouvelles infections à VIH chez les enfants à l’horizon 2015 et maintenir leurs mères en vie. Genève, ONUSIDA, 2016. 3. UNAIDS. Start free Stay free AIDS free: 2017 progress report. UNAIDS; 2017. 4. OMS. Lignes directrices unifiées sur l’utilisation des antirétroviraux pour le",
      "extractCut": true
    },
    {
      "id": "sec-031-annexes",
      "number": null,
      "title": "ANNEXES",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-032-annexe-1-mode-opératoire-normalisé-à-suivre-pour",
      "number": null,
      "title": "Annexe 1: Mode opératoire normalisé à suivre pour les résultats indéterminés",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "18",
      "labelEnd": "19",
      "words": 103,
      "summary": {
        "text": "Gives the footnotes to the standard operating procedure for indeterminate results, advising against reporting them as positive or starting treatment, prioritising new samples, and referring repeated indeterminate results to a multidisciplinary team with active follow-up of infants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "les",
          "heading": true
        },
        {
          "term": "les lignes",
          "heading": false
        },
        {
          "term": "indéterminés",
          "heading": true
        },
        {
          "term": "lignes directrices",
          "heading": false
        }
      ],
      "extract": "1. Voir les Lignes directrices unifiées 2016 de l’OMS (2016 WHO ARV Consolidated Guidelines). 2. Ne pas notifier comme positif et ne pas commencer le TAR, mais poursuivre la prophylaxie selon les lignes directrices actuelles. 3. Le laboratoire traitera en priorité les nouveaux échantillons demandés. 4. \u0007En cas de résultats à nouveau indéterminés sur deux échantillons distincts, ces résultats et les informations",
      "extractCut": true
    },
    {
      "id": "sec-033-annexe-2-procédure-à-suivre-en-cas-de-résultats",
      "number": null,
      "title": "Annexe 2: Procédure à suivre en cas de résultats discordants et d’interruption d’un traitement",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 46,
      "summary": {
        "text": "Describes an option for following up infants for at least 8 months after stopping treatment, with qualitative and viral load testing at 4 weeks, 4 months and 8 months.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mois après",
          "heading": false
        },
        {
          "term": "interruption",
          "heading": true
        },
        {
          "term": "traitement",
          "heading": true
        }
      ],
      "extract": "Cette option prévoit des soins de suivi du nourrisson pendant au moins 8 mois après l’interruption d’un TAR. Il convient si possible de procéder à un test DPN (qualitatif) et de la charge virale (quantitatif) 4 semaines, 4 mois et 8 mois après l’interruption du traitement.",
      "extractCut": false
    },
    {
      "id": "sec-034-dpn-et-charge-virale-4-semaines-4-mois-et-8-mois",
      "number": null,
      "title": "DPN et charge virale 4 semaines, 4 mois et 8 mois après l’interruption",
      "level": 3,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 34,
      "summary": {
        "text": "Defines the two scenarios in the Annex 2 diagram, depending on whether breastfeeding stops after or before the end of follow-up following treatment interruption.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "maternel survient",
          "heading": false
        },
        {
          "term": "allaitement maternel",
          "heading": false
        },
        {
          "term": "interruption",
          "heading": true
        }
      ],
      "extract": "Scénario a: L’arrêt de l’allaitement maternel survient après la fin du suivi post interruption du TAR. Scénario b: L’arrêt de l’allaitement maternel survient avant la fin du suivi post interruption du TAR. 8 mois",
      "extractCut": false
    },
    {
      "id": "sec-035-taan-1",
      "number": null,
      "title": "TAAN 1: +",
      "level": 4,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 26,
      "summary": {
        "text": "Fragmentary diagram labels showing the timeline of nucleic acid tests at 4 weeks, 4 months and 8 months after treatment interruption.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "début TAR Début de l’interruption du traitement TAAN 4 semaines après l’interruption TAAN 4 mois après l’interruption TAAN 8 mois après l’interruption TAAN 1 TAAN 2",
      "extractCut": false
    },
    {
      "id": "sec-036-taan-2",
      "number": null,
      "title": "TAAN 2: -",
      "level": 4,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 2,
      "summary": {
        "text": "A single diagram label indicating that antiretroviral therapy is continued.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "maintien TAR",
      "extractCut": false
    },
    {
      "id": "sec-037-taan-3",
      "number": null,
      "title": "TAAN 3: -",
      "level": 4,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 130,
      "summary": {
        "text": "Diagram labels for the treatment-interruption timeline, followed by a note that further follow-up accounting for breastfeeding is needed and that, if breastfeeding stops early, final status can be set by a nucleic acid test at least 6 weeks after it ends.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "taan",
          "heading": true
        },
        {
          "term": "allaitement maternel",
          "heading": false
        },
        {
          "term": "taan mois",
          "heading": false
        },
        {
          "term": "arrêt tar",
          "heading": false
        },
        {
          "term": "après arrêt",
          "heading": false
        }
      ],
      "extract": "arrêt TAR TAAN 3 Arrêt de l’allaitement maternel TDR 3 mois après l’arrêt de l’allaitement maternel Début de l’interruption du traitement TAAN 4 semaines après l’interruption TAAN 4 mois après l’interruption TAAN 8 mois après l’interruption TAAN 1 TAAN 2 TAAN 3 Arrêt de l’allaitement maternel 8 mois TAAN 1: + début TAR TAAN 2: - maintien TAR TAAN 3: - arrêt TAR Un suivi ultérieur est nécessaire pour envisager",
      "extractCut": true
    },
    {
      "id": "sec-038-annexe-3-algorithme-simplifié-pour-le-dpn",
      "number": null,
      "title": "Annexe 3: Algorithme simplifié pour le DPN",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 606,
      "summary": {
        "text": "Presents the simplified infant HIV diagnosis algorithm as flowchart text, from optional testing at birth through nucleic acid tests at 4–6 weeks and 9 months to antibody testing at 18 months or 3 months after breastfeeding ends. Lists the key principles for determining infection in HIV-exposed children under 18 months in low- and middle-income countries, including testing symptomatic children, confirmatory testing and regular follow-up with cotrimoxazole prophylaxis. Footnotes explain point-of-care use, immediate treatment with parallel confirmation, and how breastfeeding affects the timing of the final diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "allaitement maternel",
          "heading": false
        },
        {
          "term": "taan antérieurs",
          "heading": false
        },
        {
          "term": "taan pour",
          "heading": false
        },
        {
          "term": "taan chez",
          "heading": false
        },
        {
          "term": "mois après",
          "heading": false
        },
        {
          "term": "enfant exposé",
          "heading": false
        },
        {
          "term": "nourrisson enfant",
          "heading": false
        },
        {
          "term": "des anticorps",
          "heading": false
        }
      ],
      "extract": "Nouveau-né exposé au VIH (0 à 2 jours) Envisager un TAANa,b Négatif Négatif Commencer immédiatement le TARc Suivi clinique régulier Le nourrisson/l’enfant est infecté Nourrisson ou enfant exposé au VIH (de 4-6 semaines à 18 mois) Procéder à un TAANb (à 4-6 semaines ou le plus tôt possible ultérieurement) Positif Positif Commencer immédiatement le TARc Refaire un TAAN pour confirmer l’infection L’infection par le VIH",
      "extractCut": true
    },
    {
      "id": "sec-039-annexe-4-algorithme-pour-lévaluation-du-risque-d",
      "number": null,
      "title": "Annexe 4: Algorithme pour l’évaluation du risque d’infection",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 216,
      "summary": {
        "text": "Introduces an algorithm for assessing infant HIV risk at delivery, so that low-risk infants receive standard prophylaxis and high-risk infants receive enhanced postnatal prophylaxis. Lists the maternal information clinicians need, recommends viral load testing around week 36 of pregnancy, and includes fragmentary flowchart labels classifying risk.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mère séropositive",
          "heading": false
        },
        {
          "term": "risque",
          "heading": true
        },
        {
          "term": "risque élevé",
          "heading": false
        },
        {
          "term": "faible risque",
          "heading": false
        },
        {
          "term": "séropositive qui",
          "heading": false
        },
        {
          "term": "sous tar",
          "heading": false
        },
        {
          "term": "risque doit",
          "heading": false
        },
        {
          "term": "charge virale",
          "heading": false
        }
      ],
      "extract": "Cet algorithme a été établi pour faciliter l’évaluation du risque au moment de l’accouchement et le l’identification des nourrissons à haut et à faible risque d’infection: Le nourrisson à faible risque doit recevoir une prophylaxie standard (NVP ou AZT seule pour 4-6 semaines) tandis que le nourrisson à haut risque doit bénéficier d’une PPNa. Pour bien utiliser cet algorithme, le clinicien devra connaître un certain",
      "extractCut": true
    },
    {
      "id": "sec-040-la-mère-a-t-elle-été-sous-tar-pendant-4-semaines",
      "number": null,
      "title": "La mère a-t-elle été sous TAR pendant >4 semaines avant l’accouchement",
      "level": 3,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 20,
      "summary": {
        "text": "Fragmentary flowchart labels on maternal HIV status at delivery, time on treatment before delivery, and viral load above or below 1,000.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "pendant >4 semaines avant l’accouchement OUI < 1,000 OUI > 1,000 Statut sérologique de la mère AU MOMENT DE L’ACCOUCHEMENT",
      "extractCut": false
    },
    {
      "id": "sec-041-connaît-on-la-charge-virale-moins-de",
      "number": null,
      "title": "Connaît-on la charge virale moins de",
      "level": 3,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "21",
      "labelEnd": "22",
      "words": 4,
      "summary": {
        "text": "A fragment of a flowchart question asking whether the viral load is known from within 4 weeks before delivery.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "4 semaines avant l’accouchement?",
      "extractCut": false
    },
    {
      "id": "sec-042-annexe-5-posologie-et-formes-galéniques-pour-la",
      "number": null,
      "title": "Annexe 5: Posologie et formes galéniques pour la prophylaxie chez le nourrisson",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 24,
      "labelStart": "22",
      "labelEnd": "24",
      "words": 541,
      "summary": {
        "text": "Tabulates doses and formulations for enhanced postnatal prophylaxis (syrups, single-drug tablets and fixed-dose combinations) for weeks 0–6 and 6–12, with the advantages and drawbacks of each. Notes that AZT has no separate prophylactic dose and that presumptive treatment should follow age-based dosing, and ends with contact details for WHO's HIV/AIDS department and the document number WHO/CDS/HIV/18.17.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "jour comprimé",
          "heading": false
        },
        {
          "term": "nvp une",
          "heading": false
        },
        {
          "term": "azt deux",
          "heading": false
        },
        {
          "term": "deux fois",
          "heading": false
        },
        {
          "term": "posologie semaines",
          "heading": false
        },
        {
          "term": "fois par",
          "heading": false
        },
        {
          "term": "plus nvp",
          "heading": false
        },
        {
          "term": "des sirops",
          "heading": false
        }
      ],
      "extract": "Forme galénique Posologie 0-6 semaines AZT plus NVP Posologie 6-12 semaines AZT plus NVP Posologie 6-12 semaines NVP seule Observations Sirops AZT 10mg/ ml NVP 10mg/ ml 1,5 ml (15 mg) d’AZT deux fois par jour 6 ml (60 mg) d’AZT deux fois par jour 2 ml (20 mg) de NVP une fois par jour - Dosage précis de tous les produits (y compris en cas d’insuffisance pondérale à la naissance) et une même forme galénique pour les",
      "extractCut": true
    }
  ],
  "checks": {
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "pour des",
      "heading": true
    },
    {
      "term": "pour les",
      "heading": true
    },
    {
      "term": "des nourrissons",
      "heading": false
    },
    {
      "term": "chez des",
      "heading": true
    },
    {
      "term": "sur des",
      "heading": true
    },
    {
      "term": "dans des",
      "heading": false
    },
    {
      "term": "taan pour",
      "heading": true
    },
    {
      "term": "vih pour",
      "heading": true
    },
    {
      "term": "pour une",
      "heading": true
    },
    {
      "term": "les semaines",
      "heading": false
    },
    {
      "term": "par des",
      "heading": false
    },
    {
      "term": "suivi des",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 2,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "3",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "6",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 8,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "9",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 10,
      "label": "10",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "11",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 12,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 13,
      "label": "13",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 14,
      "label": "14",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 15,
      "label": "15",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 16,
      "label": "16",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 17,
      "label": "17",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 18,
      "label": "18",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 19,
      "label": "19",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 20,
      "label": "20",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 21,
      "label": "21",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 22,
      "label": "22",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 23,
      "label": "23",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 24,
      "label": "24",
      "source": "printed",
      "confidence": 0.7
    }
  ],
  "figures": [],
  "images": [
    {
      "id": "vfig-p004",
      "file": "figures/vfig-p004.webp",
      "page": 4,
      "shows": [
        "Figure 1"
      ],
      "narratives": {
        "en": "Figure 1, a horizontal stacked bar chart (in French) of mother-to-child transmission rates in the 21 Start Free, Stay Free, AIDS Free priority countries (source: UNAIDS 2018 estimates), split into transmission during the first 6 weeks and after 6 weeks. Total rates range from 26% in Indonesia (19% + 7%) and Angola (15% + 11%) down to 5% in South Africa and Botswana. The render crops the left edge, truncating some country names and the surrounding text.",
        "ar": "الشكل 1، مخطط أعمدة أفقية مكدّسة (بالفرنسية) لمعدلات انتقال العدوى من الأم إلى الطفل في البلدان الحادية والعشرين ذات الأولوية في إطار مبادرة Start Free, Stay Free, AIDS Free (المصدر: تقديرات برنامج الأمم المتحدة المشترك المعني بالإيدز لعام 2018)، مقسّمة إلى انتقال خلال الأسابيع الستة الأولى وبعدها. وتتراوح المعدلات الإجمالية بين 26% في إندونيسيا (19% + 7%) وأنغولا (15% + 11%) و5% في جنوب أفريقيا وبوتسوانا. والحافة اليسرى للصورة مقصوصة، مما يبتر بعض أسماء البلدان والنص المحيط.",
        "zh": "图1：水平堆积条形图（法文），显示“Start Free, Stay Free, AIDS Free”框架下21个重点国家的母婴传播率（来源：联合国艾滋病规划署2018年估计），分为出生后前6周内传播和6周后传播。总传播率从印度尼西亚（19%+7%）和安哥拉（15%+11%）的26%到南非和博茨瓦纳的5%不等。图像左边缘被裁切，部分国家名称和周围文字不完整。",
        "es": "Figura 1, gráfico de barras horizontales apiladas (en francés) de las tasas de transmisión maternoinfantil en los 21 países prioritarios del marco Start Free, Stay Free, AIDS Free (fuente: estimaciones del ONUSIDA de 2018), desglosadas en transmisión durante las primeras 6 semanas y después de las 6 semanas. Las tasas totales van del 26% en Indonesia (19% + 7%) y Angola (15% + 11%) al 5% en Sudáfrica y Botswana. La imagen está recortada por el borde izquierdo, lo que trunca algunos nombres de países y el texto circundante.",
        "fr": "Figure 1, diagramme en barres horizontales empilées (en français) des taux de transmission mère-enfant dans les 21 pays prioritaires du cadre Start Free, Stay Free, AIDS Free (source : estimations 2018 de l'ONUSIDA), répartis entre transmission au cours des 6 premières semaines et après 6 semaines. Les taux totaux vont de 26 % en Indonésie (19 % + 7 %) et en Angola (15 % + 11 %) à 5 % en Afrique du Sud et au Botswana. Le rendu est rogné sur le bord gauche, ce qui tronque certains noms de pays et le texte environnant.",
        "ru": "Рисунок 1 — горизонтальная столбчатая диаграмма с накоплением (на французском языке), показывающая уровни передачи ВИЧ от матери ребёнку в 21 приоритетной стране инициативы Start Free, Stay Free, AIDS Free (источник: оценки ЮНЭЙДС за 2018 год) с разбивкой на передачу в первые 6 недель и после 6 недель. Общие уровни варьируются от 26% в Индонезии (19% + 7%) и Анголе (15% + 11%) до 5% в Южной Африке и Ботсване. Изображение обрезано по левому краю, из-за чего названия некоторых стран и окружающий текст неполны."
      },
      "state": "draft"
    },
    {
      "id": "img-p006-1",
      "file": "images/img-p006-1.webp",
      "page": 6,
      "narratives": {
        "en": "Photograph of a newborn baby wrapped in a white cloth, lying down with eyes partly open.",
        "ar": "صورة فوتوغرافية لوليد ملفوف بقطعة قماش بيضاء، مستلقٍ وعيناه نصف مفتوحتين.",
        "zh": "照片：一名用白布包裹的新生儿躺着，眼睛半睁。",
        "es": "Fotografía de un recién nacido envuelto en una tela blanca, acostado y con los ojos entreabiertos.",
        "fr": "Photographie d'un nouveau-né emmailloté dans un linge blanc, allongé, les yeux entrouverts.",
        "ru": "Фотография новорождённого, запелёнатого в белую ткань; он лежит с полуоткрытыми глазами."
      },
      "state": "draft"
    },
    {
      "id": "img-p010-1",
      "file": "images/img-p010-1.webp",
      "page": 10,
      "narratives": {
        "en": "Photograph of a smiling infant girl in a yellow top leaning on the knee of an adult, against a reddish earth background.",
        "ar": "صورة فوتوغرافية لرضيعة مبتسمة ترتدي قميصاً أصفر وتستند إلى ركبة شخص بالغ، على خلفية من التراب المائل إلى الحمرة.",
        "zh": "照片：一名身穿黄色上衣、面带微笑的女婴倚靠在一名成人的膝上，背景为红褐色土地。",
        "es": "Fotografía de una niña lactante sonriente con blusa amarilla apoyada en la rodilla de un adulto, sobre un fondo de tierra rojiza.",
        "fr": "Photographie d'une petite fille souriante en haut jaune, appuyée sur le genou d'un adulte, sur fond de terre rougeâtre.",
        "ru": "Фотография улыбающейся девочки-младенца в жёлтой кофточке, опирающейся на колено взрослого, на фоне красноватой земли."
      },
      "state": "draft"
    },
    {
      "id": "img-p014-1",
      "file": "images/img-p014-1.webp",
      "page": 14,
      "narratives": {
        "en": "Photograph of a gloved health worker collecting blood from an infant's heel onto a dried blood spot card while a woman holds the infant.",
        "ar": "صورة فوتوغرافية لعامل صحي يرتدي قفازين ويجمع دماً من كعب رضيع على بطاقة بقع الدم المجففة بينما تحمل امرأة الرضيع.",
        "zh": "照片：一名戴手套的卫生工作者从婴儿足跟采血，滴到干血斑卡片上，一名妇女抱着婴儿。",
        "es": "Fotografía de un trabajador de salud con guantes que recoge sangre del talón de un lactante en una tarjeta de gota de sangre seca, mientras una mujer sostiene al lactante.",
        "fr": "Photographie d'un agent de santé ganté prélevant du sang au talon d'un nourrisson sur une carte de gouttes de sang séché, tandis qu'une femme tient le nourrisson.",
        "ru": "Фотография медицинского работника в перчатках, берущего кровь из пятки младенца на карточку для сухих пятен крови, пока женщина держит младенца."
      },
      "state": "draft"
    },
    {
      "id": "img-p016-1",
      "file": "images/img-p016-1.webp",
      "page": 16,
      "narratives": {
        "en": "Photograph of a group of women in colourful head wraps, some carrying infants, standing outdoors in a village with men in the background.",
        "ar": "صورة فوتوغرافية لمجموعة من النساء يعتمرن أغطية رأس ملونة، وتحمل بعضهن رضّعاً، يقفن في الهواء الطلق في قرية وفي الخلفية رجال.",
        "zh": "照片：一群头裹彩色头巾的妇女站在村庄户外，其中一些抱着婴儿，背景中有男子。",
        "es": "Fotografía de un grupo de mujeres con turbantes de colores, algunas con lactantes, de pie al aire libre en una aldea, con hombres al fondo.",
        "fr": "Photographie d'un groupe de femmes coiffées de foulards colorés, certaines portant des nourrissons, debout en plein air dans un village, avec des hommes à l'arrière-plan.",
        "ru": "Фотография группы женщин в ярких головных повязках, некоторые с младенцами, стоящих на улице в деревне; на заднем плане мужчины."
      },
      "state": "draft"
    },
    {
      "id": "img-p023-1",
      "file": "images/img-p023-1.webp",
      "page": 23,
      "narratives": {
        "en": "Photograph of an infant in a red top resting on the shoulder of a woman wearing an orange veil.",
        "ar": "صورة فوتوغرافية لرضيع يرتدي قميصاً أحمر ويسند رأسه إلى كتف امرأة ترتدي وشاحاً برتقالياً.",
        "zh": "照片：一名身穿红色上衣的婴儿靠在一名披着橙色面纱的妇女肩上。",
        "es": "Fotografía de un lactante con blusa roja apoyado en el hombro de una mujer con velo naranja.",
        "fr": "Photographie d'un nourrisson en haut rouge, la tête posée sur l'épaule d'une femme portant un voile orange.",
        "ru": "Фотография младенца в красной кофточке, прислонившегося к плечу женщины в оранжевом покрывале."
      },
      "state": "draft"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 43,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 44,
      "note": "4 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 6
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p3); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "found",
      "count": 3
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 39,
      "note": "39 of 44 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-329296"
  }
}
